The authors declare that they have no competing interests.
MO: study design, data collection, data interpretation and writing the manuscript; AS: study design, data collection, data interpretation; SO: statistical analysis, data interpretation, writing the manuscript; MS: statistical analysis, data interpretation, writing the manuscript; UK: data collection, data analysis, data interpretation; MA: study design, data interpretation, and revising the manuscript; SC: study design, data interpretation, and revising the manuscript; AE: study design, revising the manuscript, supervision of the research group. All authors read and approved the final manuscript.
The aim of this study was to investigate the influence of body mass index (BMI) on the in vitro fertilization (IVF) treatment outcomes in a cohort of women undergoing their first IVF, using an intracytoplasmic sperm injection (ICSI).
This retrospective cohort study included 298 cycles from women younger than 38 years old undergoing IVF-ICSI at a university infertility clinic. The treatment cycles were divided into three groups according to the BMI of the women involved: normal weight (18.5 ≤ BMI < 25 kg/m2, 164 cycles), overweight (25 ≤ BMI < 30 kg/m2, 70 cycles), and obese (BMI ≥ 30 kg/m2, 64 cycles). The underweight women (BMI < 18.5 kg/m2) were not included in the analysis due to small sample size (n = 22). The patient characteristics and IVF-ICSI treatment outcomes were compared between the BMI groups.
The total gonadotropin dose (p <0.001) and duration of stimulation (p = 0.008) were significantly higher in the obese group when compared to the normal BMI group. There were no significant differences across the BMI categories for the other IVF-ICSI cycle outcomes measured, including the number of retrieved oocytes, mature oocytes, embryos suitable for transfer, proportion of oocytes fertilized, and cycle cancellation rates (p >0.05 for each). Additionally, clinical pregnancy, spontaneous abortion, and the ongoing pregnancy rates per transfer were found to be comparable between the normal weight, overweight, and obese women (p >0.05 for each).
Obese women might require a significantly higher dose of gonadotropins and longer stimulation durations, without greatly affecting the pregnancy outcomes.
WHO. Obesity and overweight, Fact Sheet 311. Geneva: World Health Organization; 2006.
Tesauro M, Canale MP, Rodia G, Di Daniele N, Lauro D, Scuteri A, et al. Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines. Cardiol Res Pract. 2011;653182.
Gardner DK, Schoolcraft WB. In vitro culture of human blastocyst. In: Mortimer JR, editor. Toward reproductive certainty: infertility and genetics beyond 1999. Carnforth, UK: Parthenon Press; 1999. p. 378–88.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. CrossRef
Spandorfer SD, Kump L, Goldschlag D, Brodkin T, Davis OK, Rosenwaks Z. Obesity and in vitro fertilization: negative influences on outcome. J Reprod Med. 2004;49(12):973–7. PubMed
- Does obesity have detrimental effects on IVF treatment outcomes?
Munire Erman Akar
Seyit Temel Ceyhan
- BioMed Central
Neu im Fachgebiet Gynäkologie und Geburtshilfe
Meistgelesene Bücher aus dem Fachgebiet
e.Med Kampagnen-Visual, Mail Icon II